Published in Annu Rev Pathol on January 01, 2012
The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol (2013) 3.13
Reactive gliosis and the multicellular response to CNS damage and disease. Neuron (2014) 2.08
Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology (2014) 1.80
Immunopathology of multiple sclerosis. Nat Rev Immunol (2015) 1.48
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol (2014) 1.46
Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev (2012) 1.39
Quantifying the local tissue volume and composition in individual brains with magnetic resonance imaging. Nat Med (2013) 1.20
Seven-tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol (2013) 1.18
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol (2014) 1.18
Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther (2014) 1.08
Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm (2015) 1.04
Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci (2015) 0.96
Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) (2013) 0.96
Brain-reactive antibodies and disease. Annu Rev Immunol (2013) 0.94
Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. Acta Neuropathol Commun (2015) 0.93
The influence of T cell Ig mucin-3 signaling on central nervous system autoimmune disease is determined by the effector function of the pathogenic T cells. J Immunol (2013) 0.91
Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol (2015) 0.91
The progeroid gene BubR1 regulates axon myelination and motor function. Aging (Albany NY) (2016) 0.86
Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. MAbs (2013) 0.85
Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia (2014) 0.84
Myelin damage and repair in pathologic CNS: challenges and prospects. Front Mol Neurosci (2015) 0.83
Clinical and MRI phenotype of children with MOG antibodies. Mult Scler (2015) 0.82
The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci (2017) 0.82
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler (2015) 0.82
The unfolded protein response in multiple sclerosis. Front Neurosci (2015) 0.82
Inhibition of Vascular Endothelial Growth Factor Receptor 2 Exacerbates Loss of Lower Motor Neurons and Axons during Experimental Autoimmune Encephalomyelitis. PLoS One (2016) 0.82
Signalling pathways that inhibit the capacity of precursor cells for myelin repair. Int J Mol Sci (2013) 0.81
Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. J Neuroinflammation (2016) 0.81
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav (2015) 0.80
Neural Stem Cells Engineered to Express Three Therapeutic Factors Mediate Recovery from Chronic Stage CNS Autoimmunity. Mol Ther (2016) 0.80
Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis. J Biol Chem (2013) 0.80
Loss of Myelin Basic Protein Function Triggers Myelin Breakdown in Models of Demyelinating Diseases. Cell Rep (2016) 0.79
NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG. J Neuroinflammation (2015) 0.78
Microenvironmental regulation of oligodendrocyte replacement and remyelination in spinal cord injury. J Physiol (2016) 0.77
Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice. Immunol Lett (2014) 0.77
Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation. Front Immunol (2015) 0.76
Induced Stem Cells as a Novel Multiple Sclerosis Therapy. Curr Stem Cell Res Ther (2016) 0.76
Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis. J Neuroimmunol (2015) 0.76
Neuroinflammation - using big data to inform clinical practice. Nat Rev Neurol (2016) 0.75
Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery. J Neuroimmune Pharmacol (2017) 0.75
A large fraction of neocortical myelin ensheathes axons of local inhibitory neurons. Elife (2016) 0.75
Tissue transglutaminase in marmoset experimental multiple sclerosis: discrepancy between white and grey matter. PLoS One (2014) 0.75
Physiological Dynamics in Demyelinating Diseases: Unraveling Complex Relationships through Computer Modeling. Int J Mol Sci (2015) 0.75
Neuroprotective effects of vascular endothelial growth factor A in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neural Regen Res (2017) 0.75
Epigenetic Drugs for Multiple Sclerosis. Curr Neuropharmacol (2016) 0.75
Innocent Until Proven Guilty. J Neuroophthalmol (2016) 0.75
Amelioration of experimental autoimmune encephalomyelitis by clozapine is not associated with defective CD4 T cell responses. J Neuroinflammation (2017) 0.75
Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathol Commun (2017) 0.75
Baló's concentric sclerosis: imaging findings and pathological correlation. J Radiol Case Rep (2013) 0.75
Isolation of Astrocytes Displaying Myofibroblast Properties and Present in Multiple Sclerosis Lesions. Neurochem Res (2017) 0.75
Kv1.3 channel blocker (ImKTx88) maintains blood-brain barrier in experimental autoimmune encephalomyelitis. Cell Biosci (2017) 0.75
Spectral characteristics of semisolid protons in human brain white matter at 7 T. Magn Reson Med (2017) 0.75
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Gray matter involvement in multiple sclerosis. Neurology (2007) 2.75
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07
Demyelination versus remyelination in progressive multiple sclerosis. Brain (2010) 1.82
Acute disseminated encephalomyelitis: current understanding and controversies. Semin Neurol (2008) 1.72
Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest (2008) 1.67
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol (2009) 1.61
Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol (2010) 1.60
Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol (2005) 1.51
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol (2007) 1.49
Neuromyelitis optica: changing concepts. J Neuroimmunol (2007) 1.39
Bright red nuclei. Neurology (2004) 1.38
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol (2012) 1.27
Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol (2007) 1.24
The pathology of MS: new insights and potential clinical applications. Neurologist (2007) 1.19
NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers (2006) 1.14
Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve (2009) 1.13
Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol (2004) 1.10
Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol (2012) 1.09
Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol (2012) 1.07
Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem (2008) 1.06
Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions. J Neuropathol Exp Neurol (2004) 1.03
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler (2012) 1.01
Multiple sclerosis with predominant, severe cognitive impairment. Arch Neurol (2009) 0.97
Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol (2012) 0.96
Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) (2013) 0.96
Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol (2015) 0.94
CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. Am J Pathol (2003) 0.93
CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol (2005) 0.92
Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol (2014) 0.91
Cortical demyelination in CNS inflammatory demyelinating diseases. Neurology (2008) 0.91
Ornithine transcarbamylase deficiency presenting as encephalopathy during adulthood following bariatric surgery. Arch Neurol (2007) 0.90
Longitudinally extensive transverse myelitis. Curr Opin Neurol (2014) 0.90
Default mode network disruption secondary to a lesion in the anterior thalamus. Arch Neurol (2010) 0.89
Inflammatory transverse myelitis: evolving concepts. Curr Opin Neurol (2006) 0.87
N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis. Arch Neurol (2011) 0.87
Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol (2009) 0.86
Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS. Glia (2007) 0.85
Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia (2014) 0.84
Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. J Neuropathol Exp Neurol (2013) 0.83
The pathology of multiple sclerosis: evidence for heterogeneity. Adv Neurol (2006) 0.81
Evidence of aquaporin involvement in human central pontine myelinolysis. Acta Neuropathol Commun (2013) 0.80
Corrigendum: multiple sclerosis-a quiet revolution. Nat Rev Neurol (2015) 0.80
Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG. Arch Neurol (2009) 0.80
Neuromyelitis optica with extensive active brain involvement: an autopsy study. Arch Neurol (2011) 0.79
Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination. Arch Neurol (2011) 0.78
Early and widespread injury of astrocytes in the absence of demyelination in acute haemorrhagic leukoencephalitis. Acta Neuropathol Commun (2014) 0.76
Radiation-induced optic neuritis after pituitary adenoma radiosurgery in a patient with multiple sclerosis: case report. J Neurooncol (2008) 0.75